419 results on '"Raffa, R. B."'
Search Results
2. The fentanyl family: A distinguished medical history tainted by abuse
Catalog
Books, media, physical & digital resources
3. The “Darknet”: The new street for street drugs
4. Cebranopadol: novel dual opioid/NOP receptor agonist analgesic
5. Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit
6. In vitro metabolism of the analgesic agent, tramadol-N-oxide, in mouse, rat, and human
7. The evolving understanding of the analgesic mechanism of action of flupirtine
8. Cancer ‘survivor-care’: I. the α7 nAChR as potential target for chemotherapy-related cognitive impairment
9. A proposed mechanism for chemotherapy-related cognitive impairment (‘chemo-fog’)
10. Deciphering the mechanism(s) of action of natural products: analgesic peroxide oil as example
11. What do we (not) know about how paracetamol (acetaminophen) works?
12. Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced ‘chemo-fog’
13. Is a picture worth a thousand (forgotten) words?: neuroimaging evidence for the cognitive deficits in ‘chemo-fog’/’chemo-brain’
14. The M5 muscarinic receptor as possible target for treatment of drug abuse
15. Critical review of ropinirole and pramipexole – putative dopamine D3-receptor selective agonists – for the treatment of RLS
16. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies
17. Basic pharmacology relevant to drug abuse assessment: tramadol as example
18. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use
19. Is ‘chemo-fog’/‘chemo-brain’ caused by cancer chemotherapy?
20. A potential novel strategy to separate therapeutic- and side-effects that are mediated via the same receptor: β-arrestin2/G-protein coupling antagonists
21. A second (non-genomic) steroid mechanism of action: possible opportunity for novel pharmacotherapy?
22. Etoperidone, trazodone and MCPP: in vitro and in vivo identification of serotonin 5-HT1A (antagonistic) activity
23. Disruption of a drug-induced choice behavior by UV light
24. Potential novel targets for Alzheimer pharmacotherapy: I. Secretases
25. Differential tramadol and O-desmethyl metabolite levels in brain vs. plasma of mice and rats administered tramadol hydrochloride orally
26. Pharmacology of oral combination analgesics: rational therapy for pain
27. Antihistamines as analgesics
28. Could a common biochemical mechanism underlie addictions?
29. Substance P antagonists: the next breakthrough in treating depression?
30. THE POTENTIAL AND PITFALLS OF IN VIVO AFFINITY AND EFFICACY MEASURES AS APPLIED TO CENTRALLY-ACTING ANALGESICS: THE PROBLEM OF MULTIPLE MECHANISMS
31. Postoperative Pain Surveys in Italy from 2006 and 2012: (POPSI and POPSI-2)
32. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities
33. Cebranopadol: novel dual opioid/NOP receptor agonist analgesic
34. The Centers for Disease Control and Prevention opioid guidelines: potential for unintended consequences and will they be abused?
35. Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential?
36. Indirect‐acting strategy of opioid action instead of direct receptor activation: dual‐acting enkephalinase inhibitors (DENKIs).
37. Curcumin in turmeric: Basic and clinical evidence for a potential role in analgesia.
38. Nature's first “atypical opioids”: Kratom and mitragynines.
39. The role and mechanism of action of menthol in topical analgesic products.
40. The role of abuse-deterrent formulations in countering opioid misuse and abuse
41. Management of opioid-induced constipation in pregnancy: a concise review with emphasis on the PAMORAs
42. Delta opioid agonists: a concise update on potential therapeutic applications
43. The β-lactam antibiotic ceftriaxone inhibits physical dependence and abstinence Induced withdrawal from cocaine, amphetamine, methamphetamine, and clorazepate in planarians
44. Flumazenil-sensitive abstinence-induced withdrawal from benzodiazepine receptor agonists in Planaria
45. Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression
46. The clinical analgesic efficacy of buprenorphine
47. Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches
48. A modern analgesics pain ‘pyramid’
49. The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors
50. Cancer ‘survivor-care’: II. Disruption of prefrontal brain activation top-down control of working memory capacity as possible mechanism for chemo-fog/brain (chemotherapy-associated cognitive impairment)
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.